A New Zealand woman’s account of a botched weight-loss operation in Turkey is the kind of story the medical tourism industry prefers to keep in the background: the glossy promise of affordable surgery abroad, followed by months of pain, repeated corrective procedures, and a fight for accountability that appears to be going nowhere. According to RNZ, Helen Watson, a woman from Manawatū, was preparing for full stomach reconstruction surgery in February after a gastric sleeve procedure in Istanbul in September allegedly went badly wrong.
Watson told RNZ she travelled to Turkey because the numbers simply did not work in New Zealand. She reportedly paid about NZ$5,500 for the operation at Medicana in Istanbul, while private bariatric surgery at home could cost more than NZ$20,000. That price gap is exactly what makes overseas treatment so seductive. It also helps explain why more New Zealanders are getting on planes for surgery they cannot access, or cannot afford, in their own country.
But the cheap option can become brutally expensive when something goes wrong.
RNZ reported that after returning to New Zealand, Watson became seriously unwell, spent nearly two months in hospital, underwent several smaller procedures, and was then scheduled for major stomach reconstruction. Her case is not being framed as a minor complication or a disappointing cosmetic result. It is being described as a medical crisis with long-term consequences, physical and emotional.
What makes the story more troubling is the accountability gap that so often sits at the center of cross-border care. Watson says she knew almost immediately that something was wrong. Medicana, however, denied surgical failures and said the sleeve gastrectomy had been performed according to internationally accepted standards, with no intraoperative complications and no evidence of leakage at discharge. The hospital also said it did not accept that there was evidence of surgical error. In other words, the patient says the surgery destroyed her stomach; the clinic says it did nothing wrong.
That standoff is painfully familiar in medical tourism. Once the patient is back home, distance becomes a shield. Jurisdiction becomes messy. Evidence becomes contested. Legal action becomes expensive. Watson told RNZ she wanted compensation, including a refund and travel costs, but said her efforts had stalled. She also said the clinic responded aggressively after she spoke out, while Medicana said it had sought legal advice in New Zealand but had not started proceedings.
This is the darker truth behind many medical tourism success stories: when the treatment goes right, the industry celebrates global choice and lower prices. When it goes wrong, the patient can be left stranded between countries, between legal systems, and between very different versions of what happened.
The Watson case also lands in a broader pattern RNZ had already documented. In August 2025, RNZ reported that at least five New Zealand groups were offering assisted medical travel packages to Turkey, and that all of them had started within the previous two years. The same report said Turkish providers and facilitators were increasingly viewing New Zealand as an attractive market because of long waiting lists, affordability problems, and unmet demand.
That is the economic engine behind the trade. It is not just about shiny hospital marketing or influencer-friendly recovery packages. It is about pressure inside domestic health systems creating a pool of patients who feel they have run out of realistic local options. In Watson’s case, RNZ reported she did not qualify for public treatment and could not afford private surgery in New Zealand. That kind of gap is where medical tourism businesses thrive.
But public systems often end up paying part of the price anyway.
RNZ quoted Auckland bariatric surgeon Dr Richard Babor saying Middlemore Hospital was seeing increasing numbers of patients returning with post-operative problems after surgery overseas, including cases from Turkey and Mexico. He said there was almost always somebody in the hospital system dealing with complications from procedures performed abroad. He also warned that New Zealand hospitals could not realistically become follow-up services for overseas operators because they were already stretched.
That point deserves more attention than it usually gets. Medical tourism companies sell surgery as a private consumer decision, but the downstream burden does not stay private. When patients return with leaks, infections, failed procedures, or serious complications, it is often the home-country health system that stabilizes them, re-operates, and manages the aftermath. The savings are privatized upfront; the fallout is socialized later.
To be clear, overseas surgery does not always end badly, and RNZ included comments from a medical tourism operator who argued that patients should research providers carefully and that complications can happen anywhere. That is true as far as it goes. But stories like Watson’s expose how weak that reassurance can sound once a patient is facing reconstruction surgery and a foreign clinic is denying liability. “Do your research” is not a serious answer to a system built around information asymmetry, aggressive marketing, cross-border legal obstacles, and price-driven desperation.
The industry will continue to grow because the demand is real. Patients in countries like New Zealand are being pushed by cost, waiting times, and limited eligibility. Providers abroad are ready to meet that demand. But every time another case like this surfaces, it becomes harder to maintain the fantasy that medical tourism is simply smart shopping for healthcare. Sometimes it is. Sometimes it is a one-way ticket into a much bigger medical disaster.
Helen Watson’s case is ultimately about more than one clinic and one operation. It is about what happens when healthcare is marketed internationally like a bargain product, but accountability remains fragmented, expensive, and weak. The brochure sells savings. The patient may end up paying in ways no package price ever shows.
